Genetic Diseases Could See Indication Expansions Through Accelerated Approval
Executive Summary
Accelerated approvals likely to increase, particularly for cancer, predicts FDA’s Temple.
You may also be interested in...
Accelerated Approval Great For “Me-Too” Products, FDA Says
CDER’s Bob Temple explains how competitors could actually help speed up a drug approval but also hold a product to a higher standard.
FDA’s Authority Looks Safe From Judicial Interference Following Supreme Court Abortion Pill Arguments
The agency's and the pharma industry’s worst fears – that a potential ruling in the mifepristone case might usurp the FDA’s scientific authority and throw the stability of the US drug approval process into question – seem unlikely to materialize as the majority of the Supreme Court justices signal the Alliance for Hippocratic Medicine lacks standing to sue.
Bernie Gets Mostly Pharma-Friendly Drug Pricing Results
Changes to inhaler pricing may be more ‘business as usual’ for the drug industry than the Vermont senator wants to let on. FTC, meanwhile, is keeping the patent pressure on Teva, the only inhaler manufacturer to not act following Sanders’ investigation.